Lead Product(s) : OLP-1002
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OLP-1002 is an SCN9A antisense PNA and selectively inhibits the expression of Nav1.7 sodium channel in neuronal cells. It replicates much of the phenotype of people with a null mutation in the SCN9A gene. It is being investigated for chronic osteoarthrit...
Product Name : OLP-1002
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 13, 2023
Lead Product(s) : OLP-1002
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OLP-1002
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OLP-1002 is an SCN9A antisense PNA and selectively inhibits the expression of Nav1.7 sodium channel in neuronal cells. It replicates much of the phenotype of people with a null mutation in the SCN9A gene. It is being investigated for chronic osteoarthrit...
Product Name : OLP-1002
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 16, 2023
Lead Product(s) : OLP-1002
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OLP-1002
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002
Details : OLP-1002 is an SCN9A antisense peptide nucleic acid (PNA) and selectively inhibits the expression of Nav1.7 sodium channel, and therefore expected to replicate much of the phenotype of people with SCN9A channelopathy.
Product Name : OLP-1002
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 18, 2022
Lead Product(s) : OLP-1002
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable